2020 Merit Increases

Quote











anonymous said:
What % did you get?
Click to expand...

Midwest here. I got 3%... People who were hit harder with closures got nothing. Some people in the West were written up, even though they have only been in the field for 6 of the 12 months they’ve been with ITCI. I have no idea why they even held that call, last Friday. What an embarrassment! No answers, just long-winded replies that amounted to zer0. At least I have a gig, but I’ve been interviewing since February. Ship.Is.Sinking
 




anonymous said:
Midwest here. I got 3%... People who were hit harder with closures got nothing. Some people in the West were written up, even though they have only been in the field for 6 of the 12 months they’ve been with ITCI. I have no idea why they even held that call, last Friday. What an embarrassment! No answers, just long-winded replies that amounted to zer0. At least I have a gig, but I’ve been interviewing since February. Ship.Is.Sinking
Click to expand...

The ship is sinking? There is a ton of good at ITCI.

- pending new BP/MDD indications
- zero debt
- generous RSU program
- merit increases in a year where many companies froze pay increases
- no layoffs or furloughs in a pandemic year
- quarterly bonuses paid out at or above target for most of the field
- a really great product in Caplyta

I’ve been at companies that became the virtual Titanic. That’s not what is happening here.
 




It’s real simple. A plethora of things here shouldn’t be this difficult. COVID-19 or not, the launch didn’t go well. If the drug itself was great, everyone’s numbers would reflect that.
 


anonymous said:
The ship is sinking? There is a ton of good at ITCI.

- pending new BP/MDD indications
- zero debt
- generous RSU program
- merit increases in a year where many companies froze pay increases
- no layoffs or furloughs in a pandemic year
- quarterly bonuses paid out at or above target for most of the field
- a really great product in Caplyta

I’ve been at companies that became the virtual Titanic. That’s not what is happening here.
Click to expand...

Those conditions don’t exist in a vacuum. Much of the work that should have been done pre-launch is still not being done. How long do you think the company can continue to hemorrhage money? I’ve already heard from 3 friends who work out west and GM may or may not be pressuring his RBMs to push people out. PIPs were being issued as early as last summer. Several people have started planning exits. Keep an eye on openings, after the mid-year reviews are done.
 


Pending indications? They’re not going to happen. Anyway, why spend the money on the indication when most of the business is off-label.. I hope no one pulls ICD insurance data. It has happened. How do you think the OIG gets these companies fined and reps fired?
 


anonymous said:
Pending indications? They’re not going to happen. Anyway, why spend the money on the indication when most of the business is off-label.. I hope no one pulls ICD insurance data. It has happened. How do you think the OIG gets these companies fined and reps fired?
Click to expand...

Caplyta will be approved. Spending the money for approval is nothing compared to doubling our stock price when we get BPD. And we already receive and review claims data to head off compliance risk so unlikely any OIG investigation is on the horizon. We are doing this very conservatively compared to other places I’ve worked.
 




anonymous said:
It's not being done conservatively...the trials aren't up to FDA standards. There has been failed trials and heart issues in beagle dogs with the BPD trials.
Click to expand...

You do know the concern about active metabolites in beagles was addressed and put to bed in the application for schizophrenia in December 2019 right? We got a response letter from the FDA in July 2019 for additional safety data. We submitted the requested data and won approval.

BPD trials were designed in accordance with FDA requirements. Safety concerns were put to bed almost two years ago. Top line data in the BPD trials was published in September and was well received. We will get the indication.

But you probably don’t even work at Intacellular so........
 






I work here and it makes my stomach turn. Leadership is very calculating and knows how to play the game. Definitely a ton of off label use as we clearly wouldn’t make it on one indication. They say being compliant is everything but it’s not. They don’t care how the job is performed as long as it’s performed.
 





Write your reply...
Top Bottom
Back
Quote